SecurityTGXSF / Tigenix Sa
InstitutionGrifols SA
Shares39,427,978
Ownership 14.40%

Grifols SA discloses 14.40% activist ownership in TGXSF / Tigenix Sa

January 08, 2018 - Grifols SA has filed an SC 13D form with the Securities and Exchange Commission (SEC) disclosing ownership of 39,427,978 shares of Tigenix Sa (OTC:TGXSF). This represents 14.4 percent ownership of the company. In their previous filing dated July 13, 2017, Grifols SA had reported owning 9,073,538 shares, indicating an increase of 334.54 percent.

13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Reported
Shares
Change in Shares
(Percent)
Ownership
(Percent)
Change in Ownership
(Percent)
2018-01-08 2018-01-08 SC 13D 9,073,538 39,427,978 334.54 14.40 -70.19
2017-07-13 2017-07-13 SC 13G 41,929,954 16.10

Related SEC Filings

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / Cormorant Asset Management, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       SCHEDULE 13G       Under the Securities Exchange Act of 1934       (Amendment No. 2)*     TiGenix NV     (Name of Issuer)     Ordinary Shares, no par value per share     (Title of Class of Securities)     88675R109     (CUSIP Number)     December 31, 2017     (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]           

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

TGXSF / Tigenix Sa / TAKEDA PHARMACEUTICAL CO LTD - SC 13D (Activist Investment)

2018-01-12 sec.gov
SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )*     TiGenix (Name of Issuer) Ordinary shares, no nominal value (“Shares”) American Depositary Shares (“ADSs”), each representing 20 Shares (Title of Class of Securities) ISIN BE0003864817 (Shares) CUSIP 88675R109 (ADSs) (CUSIP Number) James Kehoe Takeda Pharmaceutical Company Limited 12-10, Nihonbashi 2-Chome, Chuo-ku, Tokyo 103-8668

Tigenix SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)

2017-07-13 sec.gov
Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.    )*     TiGenix   (Name of Issuer)         ordinary shares, no nominal value per share         (Title of Class of Securities)                 88675R 10 9                 (CUSIP Number)                 December 20, 2016                 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate t

Related News Stories

GRFS / Grifols Sa - Stock Institutional Ownership and Shareholders - Fintel.io

2018-02-07 fintel.io
Grifols Sa (NASDAQ:GRFS) has 209 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 153,462,260 shares. Largest shareholders include Price T Rowe Associates Inc /md/, Harding Loevner Lp, Credit Suisse Ag/, Ako Capital Llp, Artisan Partners Limited Partnership, Capital Research Global Investors, FMR LLC / Fidelity, Alliancebernstein L.

Bone Therapeutics: In (Re)Search For Money

2018-01-31 seekingalpha
On October 31, I released a focus article on Bone Therapeutics (OTC:BNZPF). On one hand, I was fairly excited about the crucial phase III interim results on osteonecrosis that are expected in H2 2018. On the other hand, I also warned investors on the less comfortable cash position of the company. In my previous estimates, I presumed a cash runway until May 2018. This article is intended to discuss recent developments concerning the company's cash position.

TGXSF / Tigenix Sa - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-12 fintel.io
Tigenix Sa (OTC:TGXSF) has 13 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 96,454,216 shares. Largest shareholders include Takeda Pharmaceutical Co Ltd, Grifols SA, Hillhouse Capital Management, Ltd., Alyeska Investment Group, L.P., Millennium Management Llc, EAM Investors, LLC, Diversified Trust Co, Deutsche Bank Ag\, Morgan Stanley, and UBS Group AG. (18-0)

Takeda's Offer On Tigenix - Good Deal Or Not?

2018-01-12 seekingalpha
On the 5th of January, shareholders of TiGenix (NASDAQ:TIG) (OTC:TGXSF) were delighted with an unexpected treat. Japanese based medicine maker Takeda (OTCPK:TKPYY) (OTCPK:TKPHF) announced its intentions to acquire the Belgium-based biotech company. Takeda is offering €1.78 per share (~$2.14) - a premium of roughly 82% based on the last closing price of €0.98. This article intends to assess the bid.

Catalan Companies Weigh an Exit as Investors Laud Their Plan B - Bloomberg

2017-10-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (17-2)




CUSIP: 88675R109